CD274 and colorectal carcinoma: An ongoing phase 2 randomized study that involves MSS–metastatic–CRC patients treated with PD-L1/cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibition, with radiotherapy, has performed TCR repertoire analysis [70].